YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Raymond James upgraded the shares of Tvardi Therapeutics (TVRD) to outperform from market perform. PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium new…
(RTTNews) - Tvardi Therapeutics, Inc. (TVRD) has reported results from its Phase 1 study of TTI-109, its next-generation STAT3 inhibitor, confirming the drug's prodrug design and improved tolerability compared to its predecessor TTI-101. T…
(RTTNews) - Today's top gainers include Universe Pharma, which expanded its pharmaceutical patent portfolio; Decoy Therapeutics, following the announcement of a PIPE financing; QuidelOrtho, on reports that it is exploring the sale of one o…
[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell…
Tvardi Therapeutics HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STA…
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Tvardi Therapeutics Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentation HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage bio…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
* Tvardi Therapeutics press release [https://seekingalpha.com/pr/20307239-tvardi-therapeutics-announces-third-quarter-2025-results-and-provides-business-update] (TVRD [https://seekingalpha.com/symbol/TVRD]): Q3 GAAP EPS of -$0.59 beats by…
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. (“Tvardi” or “the Company”) (N…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. (“Tvardi” or “the Company”) (N…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or op…
[View from Wall Street, New York City.] U.Ozel.Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. SUNDA…
Shares of Tvardi Therapeutics TVRD nosedived 83.9% on Monday after the company provided a disappointing update following an analysis of preliminary data from a mid-stage study of its lead investigational candidate, TTI-101, to treat idiopa…
[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov * Raymond James downgraded Tivardi Therapeutics (NASDAQ:TVRD [https://seekingalpha.com/symbol/TVRD]) to market perform from outperform citing the recent disappointing…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving AstraZeneca and Novo Nordisk, as well as updates fro…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.56%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +1.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.18%. December E-mini S&P futures (ESZ25) rose +1.47%, and Decemb…
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Monday closed up +1.56%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/f…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.56%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +1.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.18%. December E-mini S&P futures (ESZ25) rose +1.47%, and Decemb…
The S&P 500 Index ($SPX) (SPY) today is up +1.18%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.97%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.52%. December E-mini S&P futures (ESZ25) are up +1.12%, and December E-mini Nasd…
The S&P 500 Index ($SPX) (SPY) today is up +1.22%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.91%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.67%. December E-mini S&P futures (ESZ25) are up +1.22%, and December E-mini Nasd…
The S&P 500 Index ($SPX) (SPY) today is up +1.18%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.97%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.52%. December E-mini S&P futures (ESZ25) are up +1.12%, and December E-mini Nasd…
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +1.18%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q…
[Red down arrow on a white tiled wall. Illustration of the concept of financial crisis, recession and economic turmoil] Dragon Claws Tivardi Therapeutics (NASDAQ:TVRD [https://seekingalpha.com/symbol/TVRD]) is down ~85% in Monday trading a…
The S&P 500 Index ($SPX) (SPY) today is up +1.22%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.91%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.67%. December E-mini S&P futures (ESZ25) are up +1.22%, and December E-mini Nasd…
The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +1.22%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q…
Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology In…
Key Points GAAP EPS was $(1.00) for Q2 2025, missing analyst expectations by $0.32, or 46.9%. GAAP net income turned positive to $4.2 million in Q2 2025, driven by a $12.8 million non-operating gain. Cash position increased to $41.0 millio…
Doctor holding money by IherPhoto via iStock Clinical-stage biotech stocks carry significant risks, but also offer explosive upside potential. These companies are built around early stage innovations that, if successful, can evolve into bi…
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) announced Monday that Shaheen Wirk resigned from its board of directors on July 8. According to a statement from the company, Dr. Wirk’s decision to step down was not the result of any disagreement w…